抗病毒药物在新型冠状病毒肺炎治疗中的合理使用与药学监护

Rational use and pharmacological monitoring of antiviral drugs in the treatment of coronarirus disease 2019

在抗击新型冠状病毒肺炎(COVID-19)疫情的关键时期,国家连续颁布了7版诊疗方案,每一新版诊疗方案对治疗药物都有补充、完善。α-干扰素、磷酸氯喹、阿比多尔、洛匹那韦/利托那韦、利巴韦林等抗病毒药物得到了临床专家的广泛认可与推荐。本文从药物不良反应、药物禁忌、药物相互作用、注意事项等多个方面对《新型冠状病毒肺炎诊疗方案(试行第七版)》涉及的抗病毒药物进行归纳与总结,对抗病毒药物的合理使用与药学监护提出建议,旨在为临床治疗药物选择提供参考,提高药物治疗效果。

In the critical period of the coronarirus disease 2019(COV1 D-19)epidemic,the state has successively issued seven editions of diagnosis and treatment plan,and each new edition of diagnosis and treatment plan complements and improves the therapeutic drugs.Antiviral drugs such as interferon-alpha,chloroquine phosphate,abidol,lopinavir/ritonavir,and ribavirin have been widely recognized and recommended by clinical experts.This article summarizes the antiviral drugs involved in the "New Coronavirus Pneumonia Diagnosis and Treatment Plan(the seventh edition of the trial)" from multiple aspects such as adverse drug reactions,drug contraindications,drug interactions,and precautions,and puts forward suggestions for the rational use of antiviral drugs and pharmaceutical care,in order to provide a reference for the selection of drugs for clinical treatment and improve the effect of drug treatment.